

Ilana F Gareen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2613525/publications.pdf>

Version: 2024-02-01

61
papers

14,849
citations

172457

29
h-index

123424

61
g-index

64
all docs

64
docs citations

64
times ranked

14112
citing authors

#	ARTICLE	IF	CITATIONS
1	Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach. <i>Journal of Clinical Oncology</i> , 2022, 40, 1407-1413.	1.6	17
2	Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation. <i>JAMA Oncology</i> , 2022, 8, 579.	7.1	27
3	A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152). <i>Cancer</i> , 2022, 128, 1381-1391.	4.1	11
4	Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging. <i>JAMA Network Open</i> , 2022, 5, e2210331.	5.9	3
5	Social Genomics as a Framework for Understanding Health Disparities Among Adolescent and Young Adult Cancer Survivors: A Commentary. <i>JCO Precision Oncology</i> , 2022, , .	3.0	3
6	Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]. <i>BMC Public Health</i> , 2022, 22, .	2.9	0
7	Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy. <i>JAMA Oncology</i> , 2021, 7, 1196.	7.1	13
8	Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). <i>Radiology</i> , 2021, 301, 66-77.	7.3	17
9	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. <i>Cancer</i> , 2021, , .	4.1	3
10	Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ. <i>JAMA Network Open</i> , 2021, 4, e2129697.	5.9	6
11	Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events. <i>Cancer</i> , 2021, 127, 4546-4556.	4.1	3
12	Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 746.	7.4	268
13	Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1286.	7.4	391
14	Racial Differences in Smoking-related Disease Risk Perceptions Among Adults Completing Lung Cancer Screening: Follow-up Results from the ACRIN/NLST Ancillary Study. <i>Journal of Racial and Ethnic Health Disparities</i> , 2019, 6, 676-685.	3.2	5
15	The Restrictive IV Fluid Trial in Severe Sepsis and Septic Shock (RIFTS): A Randomized Pilot Study*. <i>Critical Care Medicine</i> , 2019, 47, 951-959.	0.9	76
16	Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. <i>JAMA Oncology</i> , 2019, 5, 1036.	7.1	23
17	Medical Care Costs Were Similar Across the Low-dose Computed Tomography and Chest X-Ray Arms of the National Lung Screening Trial Despite Different Rates of Significant Incidental Findings. <i>Medical Care</i> , 2018, 56, 403-409.	2.4	10
18	Hospice Admission and Survival After ¹⁸ F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2018, 59, 427-433.	5.0	13

#	ARTICLE	IF	CITATIONS
19	Intended Versus Inferred Treatment After ¹⁸ F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2018, 59, 421-426.	5.0	12
20	[DTâ€™01â€™01]: IMPACT OF AMYLOID PET ON PATIENT MANAGEMENT: EARLY RESULTS FROM THE IDEAS STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1474.	0.8	10
21	The Relations between False Positive and Negative Screens and Smoking Cessation and Relapse in the National Lung Cancer Screening Trial: Implications for Public Health. <i>Nicotine and Tobacco Research</i> , 2016, 18, ntv037.	2.6	34
22	Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery. <i>Journal of Oncology Practice</i> , 2016, 12, 1101-1113.	2.5	25
23	Rationale and design of the Randomized Evaluation of patients with Stable angina Comparing Utilization of noninvasive Examinations (RESCUE) trial. <i>American Heart Journal</i> , 2016, 179, 19-28.	2.7	7
24	Racial Differences in Tobacco Cessation and Treatment Usage After Lung Screening: An Examination of the National Lung Screening Trial. <i>Oncologist</i> , 2016, 21, 40-49.	3.7	17
25	Did death certificates and a death review process agree on lung cancer cause of death in the National Lung Screening Trial?. <i>Clinical Trials</i> , 2016, 13, 434-438.	1.6	24
26	Patient willingness for repeat screening and preference for CT colonography and optical colonoscopy in ACRIN 6664: the National CT Colonography trial. <i>Patient Preference and Adherence</i> , 2015, 9, 1043.	1.8	9
27	Primary Care Provider-Delivered Smoking Cessation Interventions and Smoking Cessation Among Participants in the National Lung Screening Trial. <i>JAMA Internal Medicine</i> , 2015, 175, 1509.	5.1	148
28	A Qualitative Study of Lung Cancer Risk Perceptions and Smoking Beliefs Among National Lung Screening Trial Participants. <i>Nicotine and Tobacco Research</i> , 2014, 16, 166-173.	2.6	62
29	Impact of lung cancer screening results on participant healthâ€™related quality of life and state anxiety in the National Lung Screening Trial. <i>Cancer</i> , 2014, 120, 3401-3409.	4.1	129
30	Cost-Effectiveness of CT Screening in the National Lung Screening Trial. <i>New England Journal of Medicine</i> , 2014, 371, 1793-1802.	27.0	471
31	Results of the Two Incidence Screenings in the National Lung Screening Trial. <i>New England Journal of Medicine</i> , 2013, 369, 920-931.	27.0	465
32	Identifying and collecting pertinent medical records for centralized abstraction in a multi-center randomized clinical trial: The model used by the American College of Radiology arm of the National Lung Screening Trial. <i>Contemporary Clinical Trials</i> , 2013, 34, 36-44.	1.8	5
33	Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1980-1991.	27.0	884
34	Examining whether lung screening changes risk perceptions: National Lung Screening Trial participants at 1â€™year followâ€™up. <i>Cancer</i> , 2013, 119, 1306-1313.	4.1	33
35	Racial differences in perceived risk in participants enrolled in the American College of Radiology (ACRIN-6654) arm of the National Lung Screening Trial (NLST).. <i>Journal of Clinical Oncology</i> , 2013, 31, 1563-1563.	1.6	1
36	Impact of ¹⁸ F-FDG PET Used After Initial Treatment of Cancer: Comparison of the National Oncologic PET Registry 2006 and 2009 Cohorts. <i>Journal of Nuclear Medicine</i> , 2012, 53, 831-837.	5.0	34

#	ARTICLE	IF	CITATIONS
37	The National Lung Screening Trial's Endpoint Verification Process: Determining the cause of death. <i>Contemporary Clinical Trials</i> , 2011, 32, 834-840.	1.8	17
38	Impact of Dedicated Brain PET on Intended Patient Management in Participants of the National Oncologic PET Registry. <i>Molecular Imaging and Biology</i> , 2011, 13, 161-165.	2.6	26
39	Comparative Economic Evaluation of Data from the ACRIN National CT Colonography Trial with Three Cancer Intervention and Surveillance Modeling Network Microsimulations. <i>Radiology</i> , 2011, 261, 487-498.	7.3	33
40	The National Lung Screening Trial: Overview and Study Design. <i>Radiology</i> , 2011, 258, 243-253.	7.3	992
41	Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. <i>New England Journal of Medicine</i> , 2011, 365, 395-409.	27.0	8,392
42	Baseline Characteristics of Participants in the Randomized National Lung Screening Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1771-1779.	6.3	283
43	National Institutes of Health consensus development conference statement: Management of hepatitis B. <i>Hepatology</i> , 2009, 49, S4-S12.	7.3	91
44	The impact of positron emission tomography (PET) on expected management during cancer treatment. <i>Cancer</i> , 2009, 115, 410-418.	4.1	81
45	Risk Perceptions Among Participants Undergoing Lung Cancer Screening: Baseline Results from the National Lung Screening Trial. <i>Annals of Behavioral Medicine</i> , 2009, 37, 268-279.	2.9	90
46	National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B. <i>Annals of Internal Medicine</i> , 2009, 150, 104.	3.9	329
47	Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) Alone on Expected Management of Patients With Cancer: Initial Results From the National Oncologic PET Registry. <i>Journal of Clinical Oncology</i> , 2008, 26, 2155-2161.	1.6	358
48	Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1928-1935.	5.0	186
49	The National Oncologic PET Registry (NOPR): Design and Analysis Plan. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1901-1908.	5.0	74
50	Noncompliance in cancer screening trials. <i>Clinical Trials</i> , 2007, 4, 341-349.	1.6	3
51	The Potential Impact of Differential Noncompliance In Screening Trials. <i>American Journal of Epidemiology</i> , 2006, 163, S225-S225.	3.4	0
52	Effect of Referring Physician Specialty and Practice Type on Referral for Image-Guided Breast Biopsy. <i>Journal of the American College of Radiology</i> , 2005, 2, 488-493.	1.8	1
53	Explaining the association of maternal age with cesarean delivery for nulliparous and parous women. <i>Journal of Clinical Epidemiology</i> , 2003, 56, 1100-1110.	5.0	32
54	Transportable versus Fixed Platform CT Scanners: Comparison of Costs. <i>Radiology</i> , 2003, 226, 63-68.	7.3	6

#	ARTICLE	IF	CITATIONS
55	Primer on Multiple Regression Models for Diagnostic Imaging Research. <i>Radiology</i> , 2003, 229, 305-310.	7.3	39
56	Intrauterine devices and pelvic inflammatory disease. <i>Current Women's Health Reports</i> , 2003, 3, 280-7.	0.2	6
57	Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycinâ€Resistant<i>Streptococcus pneumoniae</i>. <i>Clinical Infectious Diseases</i> , 2002, 35, 556-564.	5.8	339
58	Preferential Use of Sonographically Guided Biopsy to Minimize Patient Discomfort and Procedure Time in a Percutaneous Image-Guided Breast Biopsy Program. <i>Journal of Ultrasound in Medicine</i> , 2002, 21, 1221-1226.	1.7	42
59	Intrauterine Devices and Pelvic Inflammatory Disease: Meta-Analyses of Published Studies, 1974â€1990. <i>Epidemiology</i> , 2000, 11, 589-597.	2.7	32
60	Prognosis in Infiltrating Lobular Carcinoma. <i>American Journal of Surgical Pathology</i> , 1990, 14, 12-23.	3.7	133
61	Diagnostic quality of mammograms obtained with a new low-radiation-dose dual-screen and dual-emulsion film combination.. <i>American Journal of Roentgenology</i> , 1990, 154, 265-270.	2.2	1